Avalo Therapeutics
AVTX
8 hedge funds and large institutions have $5.32M invested in Avalo Therapeutics in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more funds holding
Funds holding: 4 → 8 (+4)
59% more capital invested
Capital invested by funds: $3.35M → $5.32M (+$1.96M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$316K |
| 2 |
Goldman Sachs
New York
|
+$178K |
| 3 |
Millennium Management
New York
|
+$138K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$19.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MAM
1
MPM Asset Management
Boston,
Massachusetts
| $2.22M | – | – | – |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $2.22M | – | – | – |
|
|
PWAM
3
Park West Asset Management
San Francisco,
California
| $340K | +$316K | +32 | New |
|
|
4
Goldman Sachs
New York
| $194K | +$178K | +18 | New |
|
|
BCCM
5
Blue Clay Capital Management
Minneapolis,
Minnesota
| $156K | – | – | – |
|
|
6
Millennium Management
New York
| $150K | +$138K | +14 | New |
|
|
7
Bank of America
Charlotte,
North Carolina
| $18K | +$19.8K | +2 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $11K | +$9.88K | +1 | New |
|
|
BIM
9
BlackRock Investment Management
Wilmington,
Delaware
| $3K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$19K | -2 | Closed |
|
AVTX Hedge Fund Activity: Q1 2016 in Review
8 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2016, worth a combined $5.32M — up 59% from $3.35M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AVTX positions and 1 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Park West Asset Management, opening a new position worth an estimated $316K. The largest seller was Citadel Advisors, exiting entirely with an estimated $19K sold.
- 8 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2016, up from 4 in Q4 2015.
- Funds reported $5.32M of Avalo Therapeutics stock for Q1 2016, up 59% quarter-over-quarter.
- 5 funds opened new Avalo Therapeutics positions in Q1 2016 and 1 closed out, a net change of +4 holders.
- The largest Avalo Therapeutics buyer in Q1 2016 was Park West Asset Management, an estimated $316K added.
- The largest Avalo Therapeutics seller in Q1 2016 was Citadel Advisors, an estimated $19K sold.
Based on aggregated 13F filings for Q1 2016.